Skip directly to site content

Panel:   Cefiderocol Verification (FDC) (Custom)
AR Bank # 0040 Klebsiella pneumoniae
Study ID: CarbaNP-09

Biosample Accession #: SAMN04014881

MLST: ST147(Pasteur)

This panels contains isolates from other AR Bank collections/panels.

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Gram Negative Carbapenemase Detection (CarbaNP)  |  Cefiderocol Verification (FDC) (Custom)  |  Piperacillin-tazobactam +aminoglycosides for Enterobacterales (PTA) (Custom)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 16R
Ampicillin >32R
Ampicillin/sulbactam 1>32R
Aztreonam >64R
Aztreonam/avibactam 10.25---
Cefazolin >16R
Cefepime >32R
Cefiderocol 21S
Cefotaxime >64R
Cefotaxime/clavulanic acid 1>32---
Cefoxitin >32R
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftazidime/clavulanic acid 1>64---
Ceftolozane/tazobactam 1>16R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 48R
Doripenem >8R
Ertapenem >8R
Gentamicin >16R
Imipenem 64R
Imipenem/relebactam 164R
Imipenem+chelators 30.5---
Levofloxacin >8R
Meropenem >8R
Meropenem-vaborbactam 1>16R
Nitrofurantoin >128R
Piperacillin/tazobactam 1>128R
Plazomicin 1S
Tetracycline >32R
Tigecycline 24I
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33

1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Molecular Mechanisms of Resistance
Aminoglycoside aac(3)-IIa, aac(6')-Ib-cr, aac(6')-Il, aph(3')-Ia, aph(6)-Id, strA
Beta-lactam VIM-27, CTX-M-15, OXA-1, SHV-11
Efflux pumps/Other EMRD, KDEA, qacEdelta1
Macrolide-Lincosamide-Streptogramin mph(A)
Phenicols/Bicyclomycins catB4
Quinolone oqxA, oqxB25
Sulfonamides sul1
Tetracyclines tet(A), tet(R)
Trimethoprim dfrA1
Truncated Porin Omp35, OmpK35
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
05/18/23MIC was updated with a new value for Aztreonam/avibactam: from --- to 0.25
05/18/23Drug was added: Aztreonam/avibactam
04/17/23Interpretation was updated with a new value for Nitrofurantoin: from --- to R
04/17/23MIC was updated with a new value for Nitrofurantoin: from --- to >128
04/17/23Drug was added: Nitrofurantoin
04/10/23Interpretation was updated with a new value for Amikacin: from S to R
03/10/23Gene was added: qacEdelta1
03/10/23Gene was added: KDEA
03/10/23Gene was added: EMRD
03/10/23Gene was added: catB4
03/10/23Gene was added: Omp35
03/10/23Gene was added: tet(R)
03/10/23Gene was added: oqxB25
03/10/23Gene was added: aph(6)-Id
03/10/23Gene was added: aac(6')-Il
03/10/23Gene was added: aac(6')-Ib-cr
03/10/23Category was added: Efflux pumps/Other
03/10/23Category was added: Phenicols/Bicyclomycins
03/10/23Gene was removed: strB
12/19/22MLST was updated: from --- to ST147(Pasteur)
02/04/22Gene was removed
02/02/22Interpretation was updated with a new value
02/02/22MIC was updated with a new value
02/02/22Drug was added
Top of Page